Hepatic Disease in HIV-Infected Patients
Summary
- Symptomatic, severe, or life-threatening drug-induced hepatic toxicity requires that all components of the drug regimen be stopped simultaneously, regardless of drug half-life
- Discontinuation of emtricitabine, lamivudine, or tenofovir disoproxil fumarate in HBV/HIV–coinfected patients requires close monitoring and treatment to prevent flares
- Treatment interruption of nevirapine for more than 2 weeks should have nevirapine reintroduced with a dose-escalation period
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content